Sir, Intravitreal bevacizumab (Avastin) for choroidal metastasis secondary to breast carcinoma: short-term follow-up Uveal metastases are the most common intraocular malignancy. The most common primary sites of cancer are from the breast (47%) and lung (21%).
1
The treatment for choroidal metastasis depends on many factors including location, multiplicity, and activity of each tumour. 1 
Bevacizumab (Avastin s
) is a full-length humanized murine monoclonal antibody against the VEGF molecule, and inhibits angiogenesis and tumour growth. 2 In this report, we describe the effect of a single intravitreal injection of bevacizumab (4 mg) in a patient with choroidal metastasis secondary to breast cancer.
Case report
A 57-year-old-woman with stage IV non-oestrogensensitive breast carcinoma with bone and lung metastasis treated with eight cicles of oxaliplatin and vinorelbine 6 months ago had rapidly decreased vision in her right eye within 2 weeks. Best-corrected visual acuity (BCVA) was 10/200 in the right eye and 20/20 in the left eye. No ocular or systemic complications were observed at the end of follow-up.
Comment
Treatment of metastatic choroidal tumour is usually recommended if the tumour appears active and threatens vision. 1 Preliminary results indicated that bevacizumab significantly extended progression-free survival in patients with locally recurrent or metastatic breast cancer. 3 The intravitreal use of bevacizumab has been published recently. The first report was for exudative choroidal neovascularization (CNV) resulting from Correspondence age-related macular degeneration (ARMD) and the other for macular oedema caused by central retinal vein occlusion. In both cases, a dramatic improvement was observed in the macula using OCT. Bevacizumab has also been used injected via pars plana for treating retinal and iris diabetic neovascularization and injected subconjunctivally in a patient with a failing bleb following trabeculectomy.
In that case, we decided to inject a higher dose of bevacizumab (4 mg) than usually recommended for most ARMD (2.5 mg) because of the severity of the disease and the dose-effect relation between bevacizumab and inhibition of angiogenesis and tumour growth.
Electrophysiological and histological studies following intravitreal injection of varying doses of bevacizumab in rabbits indicated that bevacizumab did not appear to be toxic to the retina at a concentration of 2.5 mg. 4 Assuming a rabbit vitreous cavity volume (VCV) of 1.4 ml, average human VCV (4-5 ml) is at least three times that of VCV in rabbits. Although it is difficult to directly extrapolate to humans, these studies support the safe use of intravitreal bevacizumab injection, even at theoretical doses of 7.5 mg in humans.
In our patient, 3 weeks after intravitreal injection of bevacizumab (4 mg 
